Publications
Hartung F, Patil A, Meshram R, Weber GF. Site-specific gene expression signatures of cancer metastases. Clinical and Experimental Metastasis, in press 2019.
AlSarkhi LK, Weber GF. Auto-antibodies to Osteopontin can arise in cancer. Oncology Reports 2018;40:3879-3889.
Walaszek K, Lower EE, Ziolkowski P, Weber GF. Breast cancer risk in premalignant lesions: Osteopontin splice variants indicate prognosis. British Journal of Cancer 2018;119:1259-1266. This article was the subject of a British Journal of Cancer and University of Cincinnati press release. It was featured in eurekalert.org (shared via linkedin), inpst.net, tripdatabase.com.
Weber GF. The phylogeny of Osteopontin - Analysis of the protein sequence. International Journal of Molecular Sciences 2018;19:2557.
Hartung F, Wang Y, Aronow B, Weber GF. A core program of gene expression characterizes cancer metastases. Oncotarget 2017;8:102161-102175.
Briones-Orta MA, Avendaño-Vázquez SE, Ivette Aparicio-Bautista D, Coombes JD, Weber GF, Syn WK. Prediction of transcription factor bindings sites affected by SNPs located at the osteopontin promoter. Data Brief 2017;14:538-542.
Briones-Orta MA, Avendaño-Vázquez SE, Aparicio-Bautista DI, Coombes J, Weber GF, Syn WK. Osteopontin splice variants and polymorphisms in cancer progression and prognosis. BBA Reviews on Cancer 2017:1868;93-108.
Weber GF. Time and circumstances: Cancer cell metabolism at various stages of disease progression. Frontiers in Oncology 2016:6;257 (doi: 10.3389/fonc.2016.00257). Reprinted in: Ganapathy-Kanniappan S (Ed). Cancer Metabolism: Molecular Targeting and Implications for Therapy. Lausanne: Frontiers Media 2017;7-15 (doi: 10.3389/978-2-88945-322-1).
Ramchandani D, Unruh D, Lewis CS, Bogdanov VY, Weber GF. Activation of Carbonic Anhydrase IX by alternatively spliced Tissue Factor under late-stage tumor conditions. Laboratory Investigation 2016:96;1234-1245.
Unruh D, Ünlü B, Lewis CS, Qi X, Chu Z, Sturm R, Keil R, Ahmad SA, Sovershaev T, Adam M, Van Dreden P, Woodhams BJ, Ramchandani D, Weber GF, Rak JW, Wolberg AS, Mackman N, Versteeg HH, Bogdanov VY. Antibody-based targeting of alternatively spliced Tissue Factor: a new approach to impede the primary growth and aggressiveness of pancreatic ductal adenocarcinoma. Oncotarget 2016;7:25264-25275.
Zduniak K, Agrawal A, Agrawal S, Hossain MM, Ziolkowski P, Weber GF. Osteopontin splice variants are differential predictors of breast cancer treatment responses. BMC Cancer 2016;16:441 (doi 10.1186/s12885-016-2484-x).
Weber GF. Metabolism in cancer metastasis. International Journal of Cancer 2016;138:2061-2066. This article was featured in Metastasis Research Society Newsletter, 15th August 2016.
Ramchandani D, Weber GF. Interactions between OPN and VEGF in health and disease. Implications for the skeletal system. Bone 2015;81:7-15.
Weber GF. Somnambulism and allergy. Clinical and Experimental Neuroimmunology 2015;6:321.
Weber GF. 2015. Molecular Therapies of Cancer. Switzerland (Springer), ISBN-13: 978-3-319-13277-8, ISBN-13: 978-3-319-13278-5.
Ramchandani D, Weber GF. Interactions between OPN and VEGF in health and disease. Implications for cancer. BBA Reviews on Cancer 2015;1855:202-222.
Weber GF. Molecular analysis of a recurrent sarcoma identifies a mutation in FAF1. Sarcoma 2015:Article ID 839182 (doi:10.1155/2015/839182).
Zduniak K, Ziolkowski P, Ahlin C, Agrawal A, Agrawal S, Blomqvist C, Fjällskog ML, Weber GF. Nuclear osteopontin-c is a prognostic breast cancer marker. British Journal of Cancer 2015;112:729-738. This article was featured in MDLinx (http://www.mdlinx.com/oncology/news-article.cfm/5898872/).
Shi Z, Wang B, Chihanga T, Kennedy MA, Weber GF. Energy metabolism during anchorage independence. Induction by osteopontin-c. PlosOne 2014;9:e105675.
Shen H, Weber GF. The Osteopontin-c splice junction is important for function. Molecular Carcinogenesis 2014;53:480-487.
Shi Z, Mirza M, Wang B, Kennedy MA, Weber GF. Osteopontin-a alters glucose homeostasis in anchorage independent breast cancer cells. Cancer Letters 2014;344:47-53.